基石藥業-B(02616.HK)料去年虧損收窄至不超過8億人幣
基石藥業-B(02616.HK)預計,截至去年12月31日止年度的收入總額預期將不少於4.75億元人民幣(下同),較2021年同期2.44億元幾乎升一倍。是由於已上市產品的收入增長預計將不少於3.9億元,按年增長不低於140%。
集團預料,截至去年12月31日止年度不包括以股份為基礎的付款開支的年度虧損預期將不超過8億元,較2021同期約16.97億元大幅減少不低於53%。主要由於已上市產品的收入增加以及III期註冊性臨床試驗的支出減少導致研發開支減少。該等註冊性臨床試驗已完成患者招募或已完成臨床數據讀取,同時新啟動的註冊性及早期試驗的成本較低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.